nature portfolio

Marcelo E. GUERIN
Corresponding author(s): NCOMMS-21-40384-T

Last updated by author(s): Oct 11, 2021

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

_					
5	tа	ŤΙ	ıct	ш	<u>ر</u> د

an statistical analyses, commit that the following items are present in the figure legend, table legend, main text, or Methods section.
Confirmed
$oxed{x}$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
🕱 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated

Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about <u>availability of computer code</u>

Data collection Agile

Agilent 1290 Infinity II LC System equipped with a 50 mm PLRP-S column from Agilent with 1000 Å pore size. The LC system is attached to an Agilent 6560 Ion Mobility (IM) quadrupole-time of flight (Q-TOF) mass spectrometer (Agilent, Santa Clara, CA)

Data analysis

xds VERSION Feb 5, 2021 ccp4-7.0.078 phenix-1.18.2-3874 coot 0.8.9.2 chimera 1.14 glycam-web (https://glycam.org) autodock vina 1.1.2

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio <u>guidelines for submitting code & software</u> for further information.

Data

Validation

Policy information about <u>availability of data</u>

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The atomic coordinates and structure factors have been deposited with the Protein Data Bank, accession codes 7PUJ [http://dx.doi.org/10.2210/pdb7PUJ/pdb] (EndoE-GH18L), 7PUK [http://dx.doi.org/10.2210/pdb7PUL/pdb] (EndoE-GH18L-Man5), and 7PUL [http://dx.doi.org/10.2210/pdb7PUL/pdb] (EndoE-GH20). Data are available from the corresponding authors upon reasonable request.

Field-specific reporting						
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.						
X Life sciences						
For a reference copy of	the docume	ent with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>				
Life sciences study design						
All studies must dis	All studies must disclose on these points even when the disclosure is negative.					
Sample size	No samp	sample size calculation was performed.				
Data exclusions	No data	ata was excluded from the activity experiments.				
Replication	All LC-M	MS enzymatic activity assays were performed in triplicate. All attempts at replication were successful.				
Randomization	This is no	s not relevant for this study				
Blinding	Blinding is not relevant to your study					
Departing for exacific materials, systems and mathods						
Reporting for specific materials, systems and methods						
,		uthors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, yant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.				
Materials & experimental systems Methods						
n/a Involved in th	he study	n/a Involved in the study				
Antibodies		ChIP-seq				
Eukaryotic cell lines X Flow cytometry Flow cytome						
Palaeontology and archaeology MRI-based neuroimaging						
Animals and other organisms						
Human research participants Clinical data						
Dual use research of concern						
Antibodies						
Antibodies used	Rituximab (RITUXAN, Genentech) was kindly provided courtesy of the University of Maryland Greenebaum Comprehensive Cancer Center.					

Describe the validation of each primary antibody for the species and application, noting any validation statements on the manufacturer's website, relevant citations, antibody profiles in online databases, or data provided in the manuscript.